United Therapeutics Corp
UTHR485.360USD
+6.430+1.34%
종가 02/06, 16:00（ET）시세는 15분 지연됩니다
20.82B시가총액
17.05P/E TTM
자세한 내용은 United Therapeutics Corp 회사
United Therapeutics Corporation is a pharmaceutical company. The Company markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also markets and sells an oncology product, Unituxin (dinutuximab) Injection for the treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin. Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKind’s Afrezza (insulin human) Inhalation Powder product.
United Therapeutics Corp 정보
종목 코드 UTHR
회사 이름United Therapeutics Corp
상장일Jun 17, 1999
CEORothblatt (Martine A)
직원 수1305
유형Ordinary Share
회계 연도 종료Jun 17
주소1000 Spring St
도시SILVER SPRING
증권 거래소NASDAQ OMX - NASDAQ BASIC
국가United States of America
우편 번호20910
전화13016089292
웹사이트https://www.unither.com/
종목 코드 UTHR
상장일Jun 17, 1999
CEORothblatt (Martine A)
United Therapeutics Corp의 회사 임원진
이름
이름/직위
직위
주식 보유
변동
Dr. Martine A. Rothblatt
Dr. Martine A. Rothblatt
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
666.42K
--
Mr. Paul A. Mahon, J.D.
Mr. Paul A. Mahon, J.D.
Executive Vice President, General Counsel, Corporate Secretary
Executive Vice President, General Counsel, Corporate Secretary
36.78K
--
Mr. Richard A. Giltner
Mr. Richard A. Giltner
Independent Director
Independent Director
20.57K
+1190.00%
Prof. Nilda Mesa, J.D.
Prof. Nilda Mesa, J.D.
Independent Director
Independent Director
5.29K
-187.00%
The Hon. Dr. Louis W. Sullivan, M.D.
The Hon. Dr. Louis W. Sullivan, M.D.
Independent Director
Independent Director
3.20K
+3200.00%
Mr. Michael Benkowitz
Mr. Michael Benkowitz
President, Chief Operating Officer
President, Chief Operating Officer
2.65K
+71.00%
Mr. Christopher Patusky, J.D.
Mr. Christopher Patusky, J.D.
Lead Independent Vice Chairman of the Board
Lead Independent Vice Chairman of the Board
2.59K
--
Ms. Jan Malcolm
Ms. Jan Malcolm
Director
Director
270.00
-50.00%
Mr. Raymond C. (Ray) Kurzweil, J.D.
Mr. Raymond C. (Ray) Kurzweil, J.D.
Independent Director
Independent Director
--
--
Mr. Christopher A. Causey
Mr. Christopher A. Causey
Independent Director
Independent Director
--
--
더 보기
이름
이름/직위
직위
주식 보유
변동
Dr. Martine A. Rothblatt
Dr. Martine A. Rothblatt
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
666.42K
--
Mr. Paul A. Mahon, J.D.
Mr. Paul A. Mahon, J.D.
Executive Vice President, General Counsel, Corporate Secretary
Executive Vice President, General Counsel, Corporate Secretary
36.78K
--
Mr. Richard A. Giltner
Mr. Richard A. Giltner
Independent Director
Independent Director
20.57K
+1190.00%
Prof. Nilda Mesa, J.D.
Prof. Nilda Mesa, J.D.
Independent Director
Independent Director
5.29K
-187.00%
The Hon. Dr. Louis W. Sullivan, M.D.
The Hon. Dr. Louis W. Sullivan, M.D.
Independent Director
Independent Director
3.20K
+3200.00%
Mr. Michael Benkowitz
Mr. Michael Benkowitz
President, Chief Operating Officer
President, Chief Operating Officer
2.65K
+71.00%
수익 분석
통화: USD마지막 업데이트: Tue, Jan 6
통화: USD마지막 업데이트: Tue, Jan 6
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
사업별USD
이름
수익
비율
Tyvaso DPI
336.20M
42.05%
Nebulized Tyvaso
141.80M
17.74%
Orenitram
131.10M
16.40%
Remodulin
125.90M
15.75%
Unituxin
47.90M
5.99%
기타
16.60M
2.08%
지역별USD
이름
수익
비율
United States
774.80M
96.91%
Rest of World
24.70M
3.09%
사업별
지역별
사업별USD
이름
수익
비율
Tyvaso DPI
336.20M
42.05%
Nebulized Tyvaso
141.80M
17.74%
Orenitram
131.10M
16.40%
Remodulin
125.90M
15.75%
Unituxin
47.90M
5.99%
기타
16.60M
2.08%
주식 보유 통계
마지막 업데이트: Mon, Nov 17
마지막 업데이트: Mon, Nov 17
주주
주주 유형
주주
주주
비율
BlackRock Institutional Trust Company, N.A.
9.90%
The Vanguard Group, Inc.
9.65%
Renaissance Technologies LLC
5.05%
Avoro Capital Advisors LLC
4.70%
State Street Investment Management (US)
4.47%
기타
66.24%
주주
주주
비율
BlackRock Institutional Trust Company, N.A.
9.90%
The Vanguard Group, Inc.
9.65%
Renaissance Technologies LLC
5.05%
Avoro Capital Advisors LLC
4.70%
State Street Investment Management (US)
4.47%
기타
66.24%
주주 유형
주주
비율
Investment Advisor
42.29%
Investment Advisor/Hedge Fund
33.68%
Hedge Fund
13.61%
Research Firm
2.96%
Pension Fund
2.63%
Individual Investor
1.84%
Bank and Trust
1.42%
Sovereign Wealth Fund
1.29%
Venture Capital
0.46%
기관 주식 보유
마지막 업데이트: Thu, Jan 1
마지막 업데이트: Thu, Jan 1
보고 기간
기관 수
보유 주식
비율
변동
2025Q4
1439
42.90M
99.63%
-3.07M
2025Q3
1348
44.10M
102.42%
-3.87M
2025Q2
1338
46.42M
102.62%
-2.51M
2025Q1
1369
46.67M
103.49%
-1.81M
2024Q4
1344
46.07M
102.60%
-3.00M
2024Q3
1278
45.38M
101.97%
-7.63M
2024Q2
1219
48.02M
108.26%
-2.92M
2024Q1
1151
47.12M
106.59%
-2.41M
2023Q4
1127
46.52M
99.01%
-2.26M
2023Q3
1094
46.35M
98.80%
-3.96M
더 보기
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
BlackRock Institutional Trust Company, N.A.
4.26M
9.9%
-76.88K
-1.77%
Sep 30, 2025
The Vanguard Group, Inc.
4.40M
10.22%
-31.08K
-0.70%
Sep 30, 2025
Renaissance Technologies LLC
2.17M
5.05%
+54.30K
+2.56%
Sep 30, 2025
Avoro Capital Advisors LLC
2.02M
4.7%
-347.78K
-14.67%
Sep 30, 2025
State Street Investment Management (US)
1.92M
4.47%
-244.90K
-11.30%
Sep 30, 2025
Wellington Management Company, LLP
1.40M
3.25%
-44.16K
-3.06%
Sep 30, 2025
Geode Capital Management, L.L.C.
1.25M
2.9%
+49.30K
+4.11%
Sep 30, 2025
AQR Capital Management, LLC
986.48K
2.29%
-286.68K
-22.52%
Sep 30, 2025
Darwin Global Management Ltd
748.55K
1.74%
+748.55K
--
Sep 30, 2025
Rothblatt (Martine A)
666.42K
1.55%
--
--
Dec 19, 2025
더 보기
관련 ETF
마지막 업데이트: Sat, Dec 6
마지막 업데이트: Sat, Dec 6
이름
비율
Simplify Health Care ETF
5.9%
Formidable Fortress ETF
4.22%
Franklin Genomic Advancements ETF
4.09%
First Trust NASDAQ Pharmaceuticals ETF
3.87%
Invesco Pharmaceuticals ETF
3.85%
Invesco Biotechnology & Genome ETF
3.82%
Invesco S&P MidCap Quality ETF
3.74%
Inspire Growth ETF
3.7%
VanEck Biotech ETF
3.58%
First Trust NYSE Arca Biotechnology Index Fund
3.4%
더 보기
Simplify Health Care ETF
비율5.9%
Formidable Fortress ETF
비율4.22%
Franklin Genomic Advancements ETF
비율4.09%
First Trust NASDAQ Pharmaceuticals ETF
비율3.87%
Invesco Pharmaceuticals ETF
비율3.85%
Invesco Biotechnology & Genome ETF
비율3.82%
Invesco S&P MidCap Quality ETF
비율3.74%
Inspire Growth ETF
비율3.7%
VanEck Biotech ETF
비율3.58%
First Trust NYSE Arca Biotechnology Index Fund
비율3.4%
주식 배당금
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
데이터 없음
주식 분할
날짜
배당락일
유형
비율
데이터 없음
날짜
배당락일
유형
비율
데이터 없음
